Qiaohong Lin
Papers
1
Total Citations
4
H-Index
1
About
Qiaohong Lin is a leading clinical researcher in head and neck oncology, with a focused expertise in human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). Her most impactful work pioneers neoadjuvant immunotherapy combined with chemotherapy, specifically evaluating sintilimab alongside cisplatin and nab-paclitaxel before transoral robotic surgery (TORS). In a landmark single-arm, two-centre phase 2 trial, Lin demonstrated that this regimen achieves a major pathological response (MPR) in a substantial proportion of patients, offering a paradigm shift toward de-escalation strategies that reduce the need for adjuvant radiotherapy. This study, published in 2025 and already garnering 4 citations, underscores her contribution to precision surgical oncology and immune checkpoint blockade in the neoadjuvant setting. Lin’s work directly addresses the challenge of balancing excellent oncologic outcomes with quality of life in HPV-positive patients. Her research is instrumental in defining new standards for organ-preserving, function-sparing treatment protocols. For students and clinicians, Lin exemplifies how translational phase 2 trials can reshape clinical practice, bridging immunotherapy and minimally invasive surgery to improve both survival and functional outcomes.
Research Focus
Key Achievements
Top Papers
- 1